318509926.1 Exhibit 99.1 Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates • Net Product Sales of $34.7 million, which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02), which decreased from $(0.27) for the same period in 2023. • Launched partnership with CrossLink Life Sciences, LLC to expand ZYNRELEF® promotional efforts in the first quarter of 2024. • Gross Margin improved to 76% for the quarter, up from 43% for th ...